Quantbot Technologies LP Castle Biosciences Inc Transaction History

Quantbot Technologies LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$11.66 - $26.0 $121,217 - $270,296	10,396 Added 408.49%	12,941 $177,000
Q1 2023 May 12, 2023	SELL	$19.47 - $28.49 $103,755 - $151,823	-5,329 Reduced 67.68%	2,545 $57,000
Q4 2022 Feb 13, 2023	SELL	$18.08 - $30.0 $88,031 - $146,070	-4,869 Reduced 38.21%	7,874 $185,000
Q3 2022 Nov 07, 2022	SELL	$22.51 - $34.32 $63,433 - $96,713	-2,818 Reduced 18.11%	12,743 $332,000
Q2 2022 Aug 09, 2022	BUY	$16.0 - $45.99 $248,976 - $715,650	15,561 New	15,561 $341,000
Q1 2022 May 16, 2022	SELL	$33.17 - $46.98 $102,196 - $144,745	-3,081 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$39.06 - $67.58 $254,554 - $440,418	-6,517 Reduced 67.9%	3,081 $132,000
Q3 2021 Nov 09, 2021	BUY	$60.13 - $77.6 $337,750 - $435,879	5,617 Added 141.1%	9,598 $638,000
Q2 2021 Aug 12, 2021	BUY	$50.07 - $76.78 $199,328 - $305,661	3,981 New	3,981 $291,000
Q4 2020 Feb 12, 2021	SELL	$43.6 - $73.05 $8,720 - $14,610	-200 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$38.47 - $52.03 $7,694 - $10,406	200 New	200 $10,000

203

26.2M

303K

30.3K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $739M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.